Literature DB >> 31308488

Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity.

Reyhaneh Khoshchehreh1,2, Mehdi Totonchi1,3, Juan Carlos Ramirez4, Raul Torres5,6, Hossein Baharvand1,2, Alexandra Aicher7,8, Marzieh Ebrahimi9,10, Christopher Heeschen11.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) arises through accumulation of multiple genetic alterations. However, cancer cells also acquire and depend on cancer-specific epigenetic changes. To conclusively demonstrate the crucial relevance of the epigenetic programme for the tumourigenicity of the cancer cells, we used cellular reprogramming technology to reverse these epigenetic changes. We reprogrammed human PDAC cultures using three different techniques - (1) lentivirally via induction of Yamanaka Factors (OSKM), (2) the pluripotency-associated gene OCT4 and the microRNA mir-302, or (3) using episomal vectors as a safer alternative without genomic integration. We found that induction with episomal vectors was the most efficient method to reprogram primary human PDAC cultures as well as primary human fibroblasts that served as positive controls. Successful reprogramming was evidenced by immunostaining, alkaline phosphatase staining, and real-time PCR. Intriguingly, reprogramming of primary human PDAC cultures drastically reduced their in vivo tumourigenicity, which appeared to be driven by the cells' enhanced differentiation and loss of stemness upon transplantation. Our study demonstrates that reprogrammed primary PDAC cultures are functionally distinct from parental PDAC cells resulting in drastically reduced tumourigenicity in vitro and in vivo. Thus, epigenetic alterations account at least in part for the tumourigenicity and aggressiveness of pancreatic cancer, supporting the notion that epigenetic modulators could be a suitable approach to improve the dismal outcome of patients with pancreatic cancer.

Entities:  

Mesh:

Year:  2019        PMID: 31308488      PMCID: PMC6756074          DOI: 10.1038/s41388-019-0871-x

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Mouse embryos cloned from brain tumors.

Authors:  Leyi Li; Michele C Connelly; Cynthia Wetmore; Tom Curran; James I Morgan
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

2.  Nuclear cloning of embryonal carcinoma cells.

Authors:  Robert H Blelloch; Konrad Hochedlinger; Yasuhiro Yamada; Cameron Brennan; Minjung Kim; Beatrice Mintz; Lynda Chin; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

3.  MiR-29b/TET1/ZEB2 signaling axis regulates metastatic properties and epithelial-mesenchymal transition in breast cancer cells.

Authors:  Hua Wang; Xinglan An; Hao Yu; Sheng Zhang; Bo Tang; Xueming Zhang; Ziyi Li
Journal:  Oncotarget       Date:  2017-10-31
  3 in total
  7 in total

Review 1.  Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?

Authors:  Sona Ciernikova; Julie Earl; María Laura García Bermejo; Viola Stevurkova; Alfredo Carrato; Bozena Smolkova
Journal:  Int J Mol Sci       Date:  2020-06-08       Impact factor: 5.923

Review 2.  Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.

Authors:  Kenly Wuputra; Chia-Chen Ku; Deng-Chyang Wu; Ying-Chu Lin; Shigeo Saito; Kazunari K Yokoyama
Journal:  J Exp Clin Cancer Res       Date:  2020-06-03

3.  Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment.

Authors:  Shiv Poojan; Seung-Hyun Bae; Jae-Woong Min; Eun Young Lee; Yura Song; Hee Yeon Kim; Hye Won Sim; Eun-Kyung Kang; Young-Ho Kim; Hae-Ock Lee; Yourae Hong; Woong-Yang Park; Hyonchol Jang; Kyeong-Man Hong
Journal:  Exp Mol Med       Date:  2020-07-13       Impact factor: 8.718

Review 4.  Modeling cancer progression using human pluripotent stem cell-derived cells and organoids.

Authors:  Meili Zhang; J Jeya Vandana; Lauretta Lacko; Shuibing Chen
Journal:  Stem Cell Res       Date:  2020-10-27       Impact factor: 2.020

Review 5.  Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma.

Authors:  Marcus T T Roalsø; Øyvind H Hald; Marina Alexeeva; Kjetil Søreide
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

6.  Combined transgene immortalized urothelial cells capable of reprogramming and hepatic differentiation.

Authors:  Matthias Weiand; Paula Ballmaier; Christoph Niemietz; Hartmut Schmidt; Andree Zibert
Journal:  Biochem Biophys Rep       Date:  2022-07-16

Review 7.  Cellular reprogramming to model and study epigenetic alterations in cancer.

Authors:  Jungsun Kim
Journal:  Stem Cell Res       Date:  2020-11-03       Impact factor: 2.020

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.